Skip to content

Effects of Probiotics (BioKid LR - Contains Nine Different Species of Probiotics Bacteria Including L. Reuteri) in Children With Functional Constipation

Effects of Probiotics (BioKid LR - Contains Nine Different Species of Probiotics Bacteria Including L. Reuteri) in Children With Functional Constipation: a Double Blind Randomized Control Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06959758
Enrollment
80
Registered
2025-05-07
Start date
2024-08-06
Completion date
2027-08-31
Last updated
2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Keywords

constipation, laxatives, PEG 350

Brief summary

The goal of this clinical trial is to evaluate whether a probiotic supplement, BioKid LR®, can help maintain normal bowel movements after stopping laxative treatment (PEG 3350) in children aged 6 months to 17 years with functional constipation. The main questions it aims to answer are: Does taking BioKid LR reduce the chance of constipation coming back after stopping PEG? Can BioKid LR help children maintain regular bowel movements without needing to restart laxatives? Researchers will compare children who take BioKid LR with those who take a placebo (an inactive powder) to see if the probiotic helps prevent constipation from returning. Participants will: Take PEG 3350 (a common laxative) for 12 weeks along with either BioKid LR or a placebo. After 12 weeks, begin gradually stopping PEG while continuing with BioKid LR or placebo for another 12 weeks. Then continue only with BioKid LR or placebo for an additional 28 weeks (total study duration: 52 weeks). Keep a stool diary to track bowel habits and any side effects. Attend 5 study visits for physical exams and monitoring (weeks 0, 12, 24, 38, 52). The study includes 80 children and is double-blinded, meaning neither the doctors nor the participants know who is receiving the real probiotic or the placebo. The primary outcome is how long it takes for constipation to return after stopping PEG, requiring retreatment. Secondary outcomes include: How many children still need long-term treatment. How many have regular bowel movements without accidents (in children over 4 years old). Stool consistency and frequency. Children with certain medical conditions (like celiac disease or hypothyroidism) or who are taking medications that cause constipation cannot participate. This study is supported by Supherb Group, Israel, but they are not involved in designing or analyzing the research. The study has been approved by an ethics committee and follows international ethical guidelines.

Interventions

DIETARY_SUPPLEMENTProbiotic Arm

It is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period. The study evaluates whether BioKid LR® helps maintain normal bowel movements after stopping PEG.

DRUGPlacebo

A placebo maltodextrin powder is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period.

Sponsors

Ambrosia - SupHerb Ltd.
CollaboratorINDUSTRY
Ferass Abu Hanna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Age 0.5 - 17 years 2. Diagnosis of FC based on Rome IV criteria

Exclusion criteria

1. Children with chronic diseases which could cause constipation: Celiac disease, food allergy, Hypothyroidism, Inflammatory Bowel Disease, electrolytes disturbances, Cystic fibrosis, Hirschsprung disease, Neuropathic conditions (Spinal cord trauma, Neurofibromatosis, Tethered cord) or intestinal pseudo-obstruction 2. Prematurity (\<34 weeks) 3. S/P intestinal surgery 4. Immunodeficiency 5. Malignancy 6. Children treated with medications associated with constipation. \*

Design outcomes

Primary

MeasureTime frameDescription
Constipation Recurrence52 weeksTime to recurrence of constipation after PEG withdrawal necessitating retreatment with PEG. This measures how long it takes for constipation to return after stopping laxative treatment, requiring the child to start PEG again.

Secondary

MeasureTime frameDescription
Intractable Constipation12 weeksPrevalence of intractable constipation after the initial 12 weeks of PEG treatment
Normal Bowel Movements without PEG52 weeksFailure to maintain normal bowel movements (defined as \> 3 spontaneous bowel movement per week) with no fecal incontinence (among children older than 4 year old) without necessitating PEG re-treatment, at weeks 24 and 52.

Countries

Israel

Contacts

Primary ContactFerass Abu Hanna, MD
ferass@Gmail.com00972546336583

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026